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Cardiovascular Risk in
Clopidogrel-Treated Patients According
to Cytochrome P450 2C19*2 Loss-of-Function
Allele or Proton Pump Inhibitor Coadministration
A Systematic Meta-Analysis
Jean-Sébastien Hulot, MD, PHD,* Jean-Philippe Collet, MD, PHD,† Johanne Silvain, MD,†
Ana Pena, PHD,† Anne Bellemain-Appaix, MD,† Olivier Barthélémy, MD,† Guillaume Cayla, MD,†
Farzin Beygui, MD, PHD,† Gilles Montalescot, MD, PHD†
Paris, France
Objectives The aim of this study was to assess the association between the loss-of-function cytochrome P450 2C19
(CYP2C19)*2 variant (10 studies, 11,959 patients) or the use of proton pump inhibitors (PPIs) (13 studies, 48,674
patients) and ischemic outcomes (major adverse cardiovascular events [MACE]) in patients treated with clopidogrel.
Background In clopidogrel-treated patients, increased cardiovascular risk has been identified with the loss-of-function
CYP2C19*2 allele or the use of PPIs, some of them CYP2C19 inhibitors. To further estimate the effect of a re-
duction in activity of this enzyme, the authors performed a meta-analysis of the studies available.
Methods The meta-analysis was performed on 23 studies using the odds ratio (OR) as the parameter of efficacy, with a
fixed-effect model. The end points were MACE, mortality, or stent thrombosis.
Results Of the 11,959 patients, carriers of the loss-of-function CYP2C19*2 allele (28% [n  3,418]) displayed a 30% increase
in the risk for MACE compared with noncarriers (9.7% vs. 7.8%; OR: 1.29; 95% confidence interval [CI]: 1.12 to 1.49;
p  0.001). This single gene variant (CYP2C19*2) was also associated with an excess of mortality (1.8% vs. 1.0%;
OR: 1.79; 95% CI: 1.10 to 2.91; p  0.019; n  6,225) and of stent thrombosis (2.9% vs. 0.9%; OR: 3.45; 95% CI:
2.14 to 5.57; p  0.001; n  4,905). This increased risk was apparent in both heterozygotes and homozygotes and
was independent of the baseline cardiovascular risk. PPI users (42% [n  19,614]) displayed increased risk for MACE
(21.8% vs. 16.7%; OR: 1.41; 95% CI: 1.34 to 1.48; p  0.001) and mortality (12.7% vs. 7.4%; OR: 1.18; 95% CI: 1.07
to 1.30; p  0.001; n  23,977) compared with nonusers. The impact of PPI use was, however, significantly influ-
enced by baseline cardiovascular risk, being significant only in high-risk patients.
Conclusions In this global meta-analysis, reduced CYP2C19 function appears to expose clopidogrel-treated patients to excess
cardiovascular risk and mortality. Conflicting results among studies may be explained by differences in types
and/or levels of risk of patients. (J Am Coll Cardiol 2010;56:134–43) © 2010 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.071a
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July 6, 2010:134–43 CYP2C19 Deficiency and Cardiovascular Risklopidogrel, with or without aspirin, reduces cardiovascular
vents in symptomatic vascular patients (1–3). However,
here is wide interindividual variability of response to
lopidogrel, with poor inhibition of platelet aggregation in
ome patients (4).
Metabolic activation by cytochrome P450 2C19 (CYP2C19)
as emerged as a crucial determinant of clopidogrel phar-
acodynamic response and clinical efficacy (5). CYP2C19
s a liver enzyme involved in the metabolic transformation of
he prodrug clopidogrel into its active metabolite, which
rreversibly binds to the platelet adenosine diphosphate
eceptor. CYP2C19 metabolic activity is highly variable
mong patients because of genetic variation. Several gene
ariants associated with reduced or absent CYP2C19 activ-
ty exist, although the CYP2C19*2 allele (or G681A poly-
orphism) accounts for more than 90% of cases of poor
etabolism (6–8). Carriers (approximately 30% of the
aucasian population) of the loss-of-function CYP2C19*2
llele display a reduced pharmacodynamic response to clo-
idogrel and a higher rate of recurrent cardiovascular events
ompared with noncarriers (9–16).
CYP2C19 is also inhibited by some proton pump inhib-
tors (PPI), notably omeprazole and lansoprazole (17). PPIs
re often coadministered with clopidogrel to reduce the risk
or gastrointestinal tract bleeding. Ex vivo biological studies
ave suggested that the coadministration of omeprazole or
ansoprazole may decrease the antiplatelet effect of clopi-
ogrel, whereas this interaction was not reported with other
PIs, such as pantoprazole or esomeprazole (18–22). These
tudies suggest that some PPIs may affect the conversion of
lopidogrel to its active metabolite by a possible inhibition
f CYP2C19, but the exact mechanism of this drug-drug
nteraction remains to be determined. There is also contro-
ersy as to whether the use of PPIs reduces the clinical
fficacy of clopidogrel. Several population studies have
eported that the use of PPIs increases the risk for cardiac
vents in clopidogrel-treated patients. Whether a differen-
ial effect exists between individual PPIs was unclear.
owever, the lack of risk adjustment was a limitation of
everal of these early studies.
Despite the absence of definitive evidence on the magni-
ude of risk associated with inherited or acquired reduced-
unction CYP2C19, the labeling of clopidogrel has been
ecently updated to highlight the potential impact of
YP2C19 alteration on the pharmacodynamic response to
lopidogrel and clinical outcomes of clopidogrel-treated
atients. Our objective was to perform a quantitative review of
he relationship between the reduced-function CYP2C19*2
llele or the use of PPIs and major adverse cardiovascular
vents (MACE) and mortality in patients with long-term
xposure to clopidogrel.
ethods
ligibility and search strategy. This meta-analysis was
erformed according to the checklist of the Meta-Analysis cf Observational Studies in Epi-
emiology group. We conducted
systematic search of Medline
1966 to October 1, 2009) and
he Cochrane Library (1980 to
ctober 1, 2009) for studies de-
cribing the association between
dverse outcomes in patients
ith long-term exposure to clo-
idogrel therapy and CYP2C19
enetic variants or concomitant
se of PPIs. We considered reports published in any
anguage, and we used a search approach described by Egger
nd Smith (23) to identify both observational studies and
tudies of prognosis. The search themes were combined
sing the Boolean operator AND. The first theme was
clopidogrel” and was combined with the following Medical
ubject Headings: “cytochrome P450 2C19,” “CYP2C19,”
proton pump inhibitors,” and “proton pumps.” In addition,
e searched the reference lists of all identified relevant
ublications. We finally reviewed the abstracts of selected
cientific meetings (American Heart Association, American
ollege of Cardiology, European Society of Cardiology,
nd Transcatheter Cardiovascular Therapeutics).
election criteria. Our primary objective was to determine
he specific contribution of the CYP2C19*2 loss-of-function
enetic variant and of the use of PPIs to the occurrence of
ardiovascular outcomes in patients with established coronary
rtery disease who were treated with clopidogrel.
Two authors (J.-S.H. and J.-P.C.) identified reports
ligible for further review by performing an initial screen of
dentified abstracts or titles. Reports were considered for
nclusion in the systematic review if they reported data from
riginal studies (i.e., no reviews) and reported on the use of
lopidogrel in patients. We used broad inclusion criteria for
tudies, including all indications for clopidogrel therapy.
oth reviewers fully agreed on the eligibility of reports in
his first screening. The second screening was based on
ull-text review. To be included, studies could be random-
zed or cohort studies (prospective cohort or historical
ohort) composed of patients with coronary artery disease
ho were treated with clopidogrel. Studies were selected if
hey reported on the incidence of MACE or mortality.
tudies were excluded if the primary end point was only
iological or gastrointestinal safety driven or if there was
nappropriate group comparison. Any disagreement was
esolved by consensus.
The quality of the observational and case-control studies
as assessed using the Newcastle-Ottawa quality assess-
ent scale (24). Briefly, studies were quoted using pre-
pecified items on patients’ selection (representativeness and
election of patients, ascertainment of exposure), compara-
ility of cohorts, and assessment of outcomes (recording,
dequacy of follow-up). Ratings for each item were added to
rovide a study quality score (maximal score, 10). We also
Abbreviations
and Acronyms
CI  confidence interval
CYP2C19  cytochrome
P450 2C19
MACE  major adverse
cardiovascular event(s)
OR  odds ratio
PPI  proton pump inhibitororresponded with study investigators to clarify issues.
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CYP2C19 Deficiency and Cardiovascular Risk July 6, 2010:134–43ata extraction and clinical end points. We extracted
etails on study and patient characteristics, treatment infor-
ation, specific outcomes, methods for outcome assess-
ent, and follow-up from the selected studies. These data
ere extracted independently by 2 of the authors (J.-S.H.
nd J.-P.C). Any discrepancies between reviewers were
esolved by consensus. When both abstracts and publica-
ions were available for a single study, only numbers given in
he publications were taken into account.
The primary end point was the occurrence of MACE, as
efined in each study by the occurrence of death, nonfatal
yocardial infarction, stroke, or urgent revascularization. A
econdary analysis was performed on mortality, which was
efined either as cardiovascular or overall mortality. End
oints were evaluated at the longest follow-up available.
he definition of reinfarction was different in each trial, and
e thus decided to use the trial-specific definitions of
einfarction. Definite or definite or probable stent throm-
osis according to the definition of the Academic Research
onsortium was also evaluated in studies that included
atients undergoing percutaneous coronary intervention.
tatistical analysis. The results of each trial were those
btained on an intention-to-treat basis. The meta-analysis
as performed using the odds ratio (OR) as the parameter
f efficacy with a fixed-effect model (Mantel-Haenszel),
ith appropriate tests for association and heterogeneity.
he p value for significance of association and heterogeneity
ests was set at 0.10, as previously suggested (25). Meta-
nalysis calculation (association test) and heterogeneity were
erformed using EasyMA software (26). Sensitivity analyses
ere performed according to the type of publication (ab-
tracts only vs. full-length reports), population size, and
tudy quality (higher than median and median vs. lower
han median) (23). The p value for significance was set at
.05. Potential small study bias and/or publication bias (i.e.,
he likelihood of small yet nominally significant studies
eing selectively published) was examined by visual inspec-
ion of constructed “funnel plot” and analytically with
gger’s test (27). Egger’s method plots linearly the standard
ormal deviate (natural logarithm of the relative risk/SE of
he relative risk) and precision (1/SE of the relative risk) as
ndependent variable, with test results based on the p value
f the regression constant. We also investigated relation-
hips according to the effect model analysis described by
alter. Briefly, the annual MACE rates in PPI users and
onusers were plotted for each study. A weighted regression
nalysis was then performed providing estimates of the
egression line slope and the intercept.
This meta-analysis was performed according to the Qual-
ty of Reporting of Meta-Analyses guidelines (28).
esults
earch results. Our search yielded a total of 100 potentially
elevant studies (Fig. 1). No previous meta-analyses were
dentified. A total of 23 studies, 10 on the impact of the aeduced-function CYP2C19*2 genetic variant for a total of
1,959 participants (9–11,13–16,29–31) and 13 on the
mpact of PPI coadministration for a total of 48,674
articipants (9,15,32–42), were selected. Eighteen studies
ere observational studies from prospective or retrospective
egistries, and 5 provided reanalyzed data from randomized
linical trials (Table 1). A total of 21 studies (10 of the
YP2C19*2 genetic variant and 11 of PPIs) provided data
or the occurrence of MACE, and 12 provided specific data
n mortality (9–11,13–16,29,30). Stent thrombosis was
eported in 4 studies (10,11,14,15).
ACE and stent thrombosis. Our pooled data from the 10
tudies investigating the influence of CYP2C19 genetic vari-
nts (n  11,959) showed that carriers of the CYP2C19*2
oss-of-function allele (28% [n  3,418]) displayed a signifi-
ant increase in the rate of MACE compared with noncarriers
n  331 of 3,418 [9.7%] vs. n  672 of 8,541 [7.8%]; OR:
.29; 95% confidence interval [CI]: 1.12 to 1.49; p  0.001)
Fig. 2). There was evidence of statistical heterogeneity among
he included studies (chi-square, p for heterogeneity 0.003).
There was a 3-fold increase in the rate of definite or
robable stent thrombosis in carriers of the CYP2C19*2
oss-of-function allele who underwent stent implantation
ompared with noncarriers (n  41 of 1,375 [2.9%] vs. n 
0 of 3,530 [0.9%]; OR: 3.45; 95% CI: 2.14 to 5.57; p 
.001; p for heterogeneity  0.78) (Fig. 3). A similar effect
OR: 3.79; 95% CI: 1.99 to 7.22; p  0.001) was observed
hen restricting the analysis to definite stent thrombosis
nly. The majority of stent thrombosis was subacute (47 of
1) and occurred within the first 30 days of stent implan-
ation. A publication bias was observed by visual analysis of
he funnel plot and by the mathematical estimate of the
Figure 1 Flow Diagram of the Systematic Overview Process
GI  gastrointestinal.symmetry of this plot provided by a linear regression
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July 6, 2010:134–43 CYP2C19 Deficiency and Cardiovascular Riskpproach. The intercept of the regression line did deviate
ignificantly from zero (p  0.02).
The relative contribution of heterozygotes and homozy-
otes could be evaluated in 4 of the studies representing a
otal of 5,694 of 11,959 patients (9,10,14,15). There was a
.59-fold (95% CI: 0.88 to 2.88) increased risk in heterozy-
otes and a 2.05-fold (95% CI: 1.15 to 3.63) increased risk
n homozygotes for MACE. The risk for stent thrombosis
as more than 3-fold higher in heterozygotes (2.94% vs.
.87%; OR: 3.34; 95% CI: 1.84 to 5.93) and more than
-fold higher in homozygotes (4.87% vs. 0.87%; OR: 4.68;
5% CI: 1.55 to 14.11) compared with carriers.
The pooled data for PPI coadministration showed that
PI users (42% [n 19,614]) displayed an increased risk for
ACE compared with nonusers (n  4,285 of 19,614
21.8%] vs. n  4,424 of 26,423 [16.7%]; OR: 1.41; 95%
haracteristics of the Studies Included in the Meta-AnalysisTable 1 Characteristics of the Studies Included in the Meta-An
Source
No. of
Participants With
Available Data*
Mean
Follow-Up
(yrs) Stud
CYP2C19 genetic variants
Trenk et al. (2008) (29) 797 1 Cohort
Simon et al. (2009) (9) 2,178 1 Cohort
Mega et al. (2009) (11) 1,459 1.23 Post hoc an
Collet et al. (2009) (15) 259 2.7 Cohort
Giusti et al. (2009) (14) 772 0.5 Cohort
Sibbing et al. (2009) (10) 2,485 0.08 Cohort
Anderson et al. (2009) (16) 1,250 1 Cohort
Shuldiner et al. (2009) (13) 227 1 Cohort
Worrall et al. (2009) (30) 104 1 Cohort
Bhatt (2009) (31) 2,428 2.3 Post-hoc an
PPIs
Ho et al. (2009) (32) 8,205 1.43 Cohort
Simon et al. (2009) (9) 2,208 1 Cohort
Aubert et al. (2009) (37) 16,690 1 Cohort
Collet et al. (2009) (15) 259 2.7 Cohort
Dunn et al. (2008) (36) 1,053 1 Post-hoc an
Ramirez et al. (2009) (34) 535 1 Cohort
Tsiaousis et al. (2009) (33) 612 1 Cohort
Juurlink et al. (2009) (35) 5,546 1 Nested cas
Banerjee et al. (2009) (39) 197 1.6 Cohort
Gaspar et al. (2009) (40) 922 0.5 Cohort
Sarafoff et al. (2009) (41) 2,025 0.08 Cohort
O’Donoghue et al. (2009) (38) 6,795 1.23 Post-hoc an
Bhatt (2009) (42) 3,627 0.36 Post-hoc an
Participants classified as CYP2C19*2 carriers or noncarriers or as PPI users or nonusers.
http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm). Each study was awarded a ma
utcome (3 items) categories. Two independents reviewers performed the Newcastle-Ottawa Sca
CYP2C19  cytochrome P450 2C19; MACE  major adverse cardiovascular event; MI  myocI: 1.34 to 1.48; p  0.001). There was evidence of htatistical heterogeneity among the included studies (chi-
quare, p  0.001) (Fig. 2). When analyzing individual
PIs, we found that omeprazole was the most frequently
rescribed PPI (50.3%), followed by pantoprazole (19.8%)
nd esomeprazole (19.3%). Rabeprazole and lansoprazole
ere prescribed in small portions of patients. In 4 studies,
e were able to isolate data on the risk associated with
meprazole intake. We found that compared with PPI
onusers, omeprazole users displayed a significantly higher
isk for MACE (n  1,597 of 8,392 [19.0%] vs. n  2,532
f 15,246 [16.6%]; OR: 1.37; 95% CI: 1.27 to 1.47;
 0.001).
When combining all data (n  55,529), we found that
lopidogrel-treated patients who presented with putative
YP2C19 deficits due to carriage of the CYP2C19*2
oss-of-function allele or drug-drug interaction with PPIs
s
Outcomes
No. of Events
for Each
Outcome
Quality
Score†
MACE (death/MI) 24 9
MACE (death/MI/stroke) 288 8
of RCT MACE (death/MI/stroke)
Death
129
12
9
MACE (death/MI/revascularization)
Death
26
3
9
MACE (death/MI)
Death
29
18
9
MACE (death/MI/stroke)
Death
177
21
9
MACE (death/MI)
Death
137
24
8
MACE (death/MI) 30 9
MACE 10 7
of RCT MACE (death/MI/stroke) 153 9
MACE (death/MI)
Death
2,176
1,535
9
MACE (death/MI/stroke) 294 8
MACE (death/MI/stroke) 3,479 6
MACE (death/MI/revascularization)
Death
26
3
9
of RCT MACE (death/MI/stroke) 89 8
MACE (death/MI/revascularization)
Death
47
27
7
Death 21 6
ol MACE (death/MI)
Death
1,513
531
5
MACE (death/MI/revascularization/stroke) 90 8
MACE (death/MI/revascularization) 78 5
Death 20 6
of RCT MACE (death/MI/stroke)
Death
781
150
9
of RCT MACE (death/MI/stroke) 136 9
quality score was determined according to The Newcastle-Ottawa Scale for cohort studies
of 1 star for each numbered item within the selection (4 items), comparability (2 items), and
ng. Discrepancies were solved by a third independent reviewer.
farction; PPI  proton pump inhibitor; RCT  randomized controlled trial.alysi
y Type
alysis
alysis
alysis
e-contr
alysis
alysis
†The
ximumad a 42% increase in the risk for MACE occurrence (OR:
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CYP2C19 Deficiency and Cardiovascular Risk July 6, 2010:134–43.42; 95% CI: 1.35 to 1.49; p  0.001) (Fig. 2). For this
ooled analysis, data from TRITON (Trial to Assess
mprovement in Therapeutic Outcomes by Optimizing
latelet Inhibition With Prasugrel) were obtained from the
riginal genetic analysis (11). Data from the PPI analysis led
o a similar trend (OR: 1.43; 95% CI: 1.36 to 1.50; p 
.001; n  48,015) (38).
0       0.5 1      1.5        2      
OR 1.42; 9
Figure 2 ORs for MACE According to CYP2C19*2 Allele (n  1
The incidence of major adverse cardiovascular events (MACE) was higher among c
users of proton pump inhibitors (PPIs). The analysis for heterogeneity was significa
interval; OR  odds ratio.
0 1 2 3 4 5 10 20
Figure 3 ORs for Stent Thrombosis (n  4,905)
According to CYP2C19*2 Allele
The incidence of stent thrombosis was higher among carriers of the
CYP2C19*2 reduced-function allele. The analysis for heterogeneity was not
significant. Data were not available in the studies of proton pump inhibitors.
OR, fixed model, bilateral CI, 95% for trials, 95% for meta-analysis. Abbrevia-
tions as in Figure 2.sortality. Data on mortality were extracted from 5 studies
valuating the effect of the CYP2C19*2 genetic variant and
rom 7 studies looking at the impact of PPI coadministra-
ion. Carriage of the CYP2C19*2 gene variant was associ-
ted with an excess of all-cause mortality (n  32 of 1,745
1.8%] vs. n  46 of 4,480 [1.0%]; OR: 1.79; 95% CI: 1.10
o 2.91; p  0.019; p for heterogeneity  0.063). Similar
esults were observed on cardiovascular mortality. We also
bserved an excess of mortality in PPI users compared with
onusers (n  1,228 of 9,644 [12.7%] vs. n  1,059 of
4,333 [7.4%]; OR: 1.18; 95% CI: 1.07 to 1.30; p  0.001;
for heterogeneity  0.13). There was no evidence of
eterogeneity among the included trials. Finally, when
ombining all data, we also found that clopidogrel-treated
atients who presented with putative CYP2C19 deficits due
o carriage of the CYP2C19*2 loss-of-function allele or
rug-drug interaction with PPIs had a 20% increased risk
or death (OR: 1.20; 95% CI: 1.09 to 1.32; p  0.001; p for
eterogeneity  0.021) (Fig. 4). No publication biases were
bserved either for carriage of CYP2C19*2 or PPI use alone or
ombined both on funnel plot inspection and Egger’s test.
ensitivity analyses. The random-effect analyses of MACE
nd mortality yielded effect sizes that were similar in magni-
ude and direction to those obtained with the fixed-effect
nalyses (Online Table 1). The results of the sensitivity
nalyses to assess the influence of the status of publication,
       8         16  
I: 1.35-1.49, p<0.001; phet<0.001 (n=55529)
9) and PPI Use (n  46,037)
of the cytochrome P450 2C19 (CYP2C19)*2 reduced-function allele and in
both analyses (p  0.003 and p  0.001, respectively). CI  confidence   4   
5% C
1,95
arriers
nt forample size, and study quality on the impact of CYP2C19*2
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July 6, 2010:134–43 CYP2C19 Deficiency and Cardiovascular Riskenetic variant or PPI coadministration on MACE occurrence
re reported in Tables 2 and 3, respectively. After exclusion of
he studies with the lowest quality score or the smallest
umbers of patients, the magnitudes and directions of the
ffects of either the CYP2C19*2 allele or the use of PPIs in
lopidogrel-treated patients remained similar. Large sample
izes and high-quality studies yielded similar conclusions on
he detrimental impact of inherited or acquired CYP2C19
educed function in clopidogrel-treated patients.
To investigate whether the effect of PPIs in clopidogrel-
reated patients could be related to the incidence of MACE
n the studied population, we thus performed an effect
odel analysis with the use of Walter’s weighted regression
odel, testing the relationship between the annual MACE
ate in PPI nonusers versus PPI users in each study. The
lope of the regression line was different from 1 (1.59; 95%
0         0.1        0.3    1.0       2     
2C19*2 better 2C19*
Figure 4 ORs for Death According to CYP2C19*2 Allele (n  6
The incidence of death was higher among carriers of the CYP2C19*2 reduced-func
The analyses for heterogeneity were not significant. OR, fixed model, bilateral CI, 9
ensitivity Analyses of CYP2C19 Genetic VariantsTable 2 Sensitivity Analyses of CYP2C19 Genetic Variants
Subgroup
No. of
Studies
Total No. of
Patients
MACE
CYP2C19*2
Overall 10 11,959 331/3,4
Published (full-length report) 7 8,177 225/2,3
Unpublished 3 3,782 106/1,0
Large size (n  1,000) 5 9,800 278/2,7
Small size (n  1,000) 5 2,159 53/65
High-quality study* 7 8,427 205/2,4
Low-quality study 3 3,532 126/99
High-risk patients† 5 5,218 186/1,4
Low-risk patients 5 6,741 145/1,9
he influence of the status of publication, sample size, and study quality on the impact of inherited
atients was evaluated. *A high-quality study was defined as one having a Newcastle-Ottawa Sc
ACE 7% in the control group.
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.I: 1.42 to 1.76; p  0.001), and the 95% CI of the
ntercept did not include the origin (0.047; 95% CI:
0.074 to 0.022; p  0.006), demonstrating that the
ffect model was mixed (Fig. 5). The regression line
ntersected with the bisector (the reference line indicating
he lack of difference between groups) at an annual MACE
ate of 8%, suggesting that the impact of PPIs depends on
he incidence of events in the PPI nonusers and that the
mpact of PPIs per se should be seen only in patients with
he highest baseline risk for MACE.
We then assessed whether the effect of PPIs was influ-
nced by the baseline cardiovascular risk of patients (Table 3).
tudies were considered to include high-risk patients when
he rate of MACE was superior to 10% (the median value
f all studies) in PPI nonusers. PPI users had a significantly
igher risk for MACE when considering the 6 studies with
       50      250 
se
) and PPI Use (n  23,977)
llele and in users of PPIs.
r trials, 95% for meta-analysis. Abbreviations as in Figure 2.
rs
MACE in
Noncarriers OR (95% CI) p Value
p Value for
Heterogeneity
672/8,541 1.29 (1.12–1.49) 0.001 0.003
478/5,853 1.25 (1.05–1.48) 0.01 0.001
194/2,688 1.40 (1.09–1.80) 0.008 0.66
606/7,038 1.20 (1.03–1.40) 0.02 0.07
66/1,503 2.16 (1.46–3.21) 0.001 0.06
363/6,000 1.48 (1.23–1.77) 0.001 0.04
309/2,541 1.06 (0.85–1.33) 0.60 0.04
408/3,765 1.22 (1.01–1.47) 0.04 0.02
264/4,776 1.40 (1.13–1.74) 0.002 0.02
9 reduced function related to CYP2C19*2 genetic variant carriage on MACE in clopidogrel-treated
re 9 (the median value of all studies). †High-risk patients were defined as an annual rate of    10 
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.001), while no effect was observed in the remaining 7 studies
ncluding low-risk patients (OR: 1.01; 95% CI: 0.88 to 1.16;
 0.84). Of interest, the impact of the CYP2C19*2 allele
as found irrespective of the cardiovascular risk level of
atients using a similar approach (Table 2).
iscussion
lopidogrel is a prodrug that requires biotransformation
nto its active metabolite, which binds irreversibly to the
latelet adenosine diphosphate membrane receptor. In vivo
eneration of the active metabolite is highly variable, re-
uiring a polymorphic hepatic CYP2C19 enzyme for clo-
idogrel activation. In coronary patients who carry the
enetic variant associated with a loss of function of the
YP2C19 enzyme, the risk for stent thrombosis on clopi-
ensitivity Analyses of the Impact of PPI CoadministrationTable 3 Sensitivity Analyses of the Impact of PPI Coadministra
Subgroup
No. of
Studies
Total No. of
Patients
MACE in P
Users
Overall 11 46,037 4,285/19,6
Published (full-length report) 5 23,013 2,389/10,3
Unpublished 6 23,024 1,896/9,30
Large size (2,000 patients) 6 43,071 4,164/18,8
Small size (2,000 patients) 5 2,966 121/751
High-quality study* 7 22,344 2,185/11,2
Low-quality study 4 23,693 2,100/8,33
High-risk patients† 6 33,768 3,921/15,1
Low-risk patients 7 12,269 364/4,46
he influence of the status of publication, sample size, and study quality on the impact of acquired
valuated. *A high-quality study was defined as one having a Newcastle-Ottawa Scale score 8 (th
ontrol group.
Abbreviations as in Tables 1 and 2.
Slope: 1.59 95% CI (1.42-1.76)
Intercept: -0.048 95% CI (-0.074-0.022)
Risk in PPI non-users
R
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Banerjee et al.
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Aubert et al.
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Ho et al.
0.08
Figure 5 Effect Model Analysis of PPI Use on MACE
Weighted regression line (solid red line) is shown between annual incidence of
major adverse cardiovascular events (MACE) in proton pump inhibitor (PPI) non-
users (x axis) and PPI users (y axis). The bisector (dashed red line) represents
the lack of difference between groups. The regression line intersects the bisec-
tor at an annual MACE rate of 8% in PPI nonusers. Abbreviation as in Figure 2.cogrel treatment is 3- to 6-fold higher (9–11,14–16,29).
owever, the influence and magnitude of risk of the
YP2C19 genotype have been inconsistent among studies.
n addition, a recent concern relates to PPIs metabolized by
he same CYP2C19 enzyme (suggesting a potential inter-
erence with the conversion of clopidogrel into its active
orm), reducing clopidogrel’s antiplatelet effect and increas-
ng the risk for cardiovascular events (9,32–37). Our results
uggest that carriers of a reduced-function CYP2C19 allele
nd/or users of PPIs have approximately a 40% increased
isk for MACE when they are treated with clopidogrel. One
f the most important contributions of our meta-analysis is
he 20% higher risk for death observed in these patients.
he other striking finding is that the detrimental effect of
PIs may only exist in high-risk patients as opposed to that
f carriage of CYP2C19*2 allele, which was observed
rrespective of patients’ cardiovascular risk levels.
Several clinical studies have recently demonstrated the
elationship between variants in the CYP2C19 gene and the
isk for adverse cardiovascular outcome in clopidogrel-
reated patients (9–11,13–16,29). However, risk estimates
ad wide CIs, and no significant effect on mortality was
oted in most studies. We report here the impact of this
ingle gene variant (CYP2C19*2) on mortality in patients
xposed to clopidogrel. All patients who contributed to the
ortality end point (6,225 of 11,959) were at high risk. All
nderwent stent implantation, and two-thirds presented
ith acute coronary syndromes. Obviously, carriage of
YP2C19*2 may have contained the effect of clopidogrel
nd left the patients insufficiently protected.
The hazard of reduced-function CYP2C19 allele carriage
as even more striking for stent thrombosis, a serious
omplication of percutaneous coronary intervention (43). It
s noteworthy that the magnitude of stent thrombosis excess
ssociated with carriage of the CYP2C19*2 genetic variant
as similar to the excess of risk observed with early
lopidogrel discontinuation (12,44). Warnings have been
elivered by scientific societies against early or inappropriate
MACE in PPI
Nonusers OR (95% CI) p Value
p Value for
Heterogeneity
4,424/26,423 1.41 (1.34–1.48) 0.001 0.001
2,401/12,701 1.32 (1.23–1.42) 0.001 0.001
2,023/13,722 1.50 (1.40–1.61) 0.001 0.02
4,215/24,208 1.41 (1.34–1.49) 0.001 0.001
209/2,215 1.35 (1.03–1.76) 0.03 0.05
1,407/11,061 1.33 (1.23–1.44) 0.001 0.001
3,017/15,362 1.47 (1.37–1.57) 0.001 0.02
3,709/18,614 1.49 (1.41–1.57) 0.001 0.001
715/7,809 1.01 (0.88–1.16) 0.84 0.14
19 reduced function related to PPI coadministration on MACE in clopidogrel-treated patients was
ian value of all studies). †High-risk patients were defined as an annual rate of MACE 10% in thetion
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July 6, 2010:134–43 CYP2C19 Deficiency and Cardiovascular Riskur meta-analysis suggests that similar warnings could be
iven to carriers of the CYP2C19*2 allele treated with
lopidogrel after stent implantation, and our findings sup-
ort the recent changes in the labeling of clopidogrel.
ndeed, the vast majority of stent thromboses were subacute,
nd the question arises now whether rapid genetic testing
or the CYP2C19*2 variant after stent implantation has
linical relevance to adjust treatment in patients genetically
xposed to a poor response to clopidogrel. This specific issue
s currently investigated in the ongoing ARCTIC-GENE
Assessment With a Double Randomization of a Monitoring-
djusted Antiplatelet Treatment Versus a Common Anti-
latelet Treatment for DES Implantation and Interruption
ersus Continuation of Double Antiplatelet Therapy, One
ear After Stenting) study (NCT00827411). Meanwhile, it
ppears reasonable to identify CYP2C19*2 loss of function
n patients receiving stents with associated clinical features
f poor functional response to clopidogrel (i.e., recurrent
vents while on clopidogrel, overweight, diabetes).
The relative contributions of heterozygotes and homozy-
otes could not be assessed in the entire cohort of studies.
his information was obtained in only 4 of the studies,
epresenting 5,694 of 11,959 patients. We found that there
as an increased risk for the occurrence of MACE in
eterozygotes, which however did not reach significance as
pposed to homozygotes. However, because of the low
requency of homozygotes in the population (3% of
atients, about 10% of CYP2C19*2 carriers), it is likely that
he detrimental impact of carriage of CYP2C19*2 observed
n all carriers (heterozygotes and homozygotes) may result
rom increased risk in both homozygotes and heterozygotes.
he relative contributions of heterozygotes and homozy-
otes may also vary according to clinical presentation. We
ere able to detect a significant gene-dose effect on the risk
or stent thrombosis in patients who had undergone percu-
aneous coronary intervention, whereas preliminary results
rom the CHARISMA (Clopidogrel for High Athero-
hrombotic Risk and Ischemic Stabilization, Management,
nd Avoidance) genomic substudy indicated no reduction in
rug response in CYP2C19*2 heterozygotes. This may be
ttributable to the characteristics of the patient population,
hich was composed of stable patients without recent acute
oronary syndromes or stent implantation. However, inclu-
ion of the CHARISMA results in our meta-analysis did
ot change the overall results, demonstrating the significant
nfluence of the CYP2C19*2 allele.
Obviously, clinical implications are relevant. Carriers of
he loss-of-function CYP2C19*2 allele represent approxi-
ately 30% of the Caucasian population and up to 50% in
ast Asians, and heterozygotes represent 90% of the carri-
rs. Prospectively and adequately powered randomized
tudies are ongoing, and the question arises whether rapid
enetic testing will play a role when new platelet adenosine
iphosphate receptor inhibitors, namely prasugrel and ti-
agrelor, enter the market for patients with acute coronary
yndromes undergoing coronary interventions. Indeed, a menomewide association study has pointed out that the
olymorphic hepatic CYP2C19 enzyme accounts for only
2% of the variation in response to the thienopyridine agent
lopidogrel (13). Other genetic and environmental factors
ay play a role and need to be clarified.
Several studies have clearly established a similar negative
iological interaction between PPIs and clopidogrel (18–21).
ecent clinical investigations have reported that such an
nteraction may lead to a significant increase in cardiovascular
isk, persisting after adjustment for potential confounders (32).
lthough the association was not significant for mortality,
everal medicines regulators have issued public statements on
his interaction between clopidogrel and PPIs and have rec-
mmended changes in the product information for all
lopidogrel-containing medicines to discourage the concomi-
ant use of PPIs unless absolutely necessary. These recommen-
ations have been debated. Indeed, there are inconsistencies
mong these recent clinical investigations, some of them
uggesting that PPI use per se rather than an interaction with
lopidogrel may be a marker of hazard (36). In addition,
arious PPIs affect to different degrees the metabolism of
lopidogrel and may have different impacts on clinical out-
omes. Our meta-analysis provides evidence that the concom-
tant use of clopidogrel and PPIs is associated with an increased
isk for MACE and mortality, supporting the recent recom-
endations from the regulators. The majority of patients
ncluded in the meta-analysis were treated with omeprazole,
he most potent CYP2C19 inhibitor.
The influence of PPIs was, however, highly heteroge-
eous between studies. The question arises why the negative
nfluence of PPIs on the antiplatelet effects of clopidogrel
eported in previous studies did not translate into worse
linical outcomes in the post hoc analysis of TRITON (38)
nd in COGENT (Clopidogrel and the Optimization of
astrointestinal Events Trial) (n  3,627) (42), the first
andomized phase 3 study testing a combination of 20-mg
meprazole and clopidogrel versus placebo and clopidogrel
n patients requiring clopidogrel for at least 12 months. Our
esults provide evidence that the impact of PPIs in terms of
linical outcomes depends on the baseline cardiovascular
isk for clopidogrel-treated patients. We did not observe any
ignificant influence of PPIs in clopidogrel-treated patients,
ith an annual rate of MACE lower than 10% (OR: 1.01;
5% CI: 0.88 to 1.16; p  0.84), while the PPI effect was
ighly significant in patients, with an annual rate of MACE
igher than 10% (OR: 1.49; 95% CI: 1.41 to 1.57; p 0.001).
esults from TRITON and preliminary results from
OGENT provide reassurance that there is probably no
linically relevant adverse cardiovascular interaction between
lopidogrel and PPIs in selected low-risk patients. Evalua-
ion of the annual rate of MACE in the PPI nonusers
rovides evidence that patients recruited in these trials do
ot resemble the higher risk patients from other studies
ncluded in the present meta-analysis. Registries may recruit
ore patients with reduced responses to clopidogrel that
ay have been further reduced by the drug–drug interac-
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CYP2C19 Deficiency and Cardiovascular Risk July 6, 2010:134–43ion. However, a causative link between PPI use and
lopidogrel response cannot be inferred from our analysis.
hether the detrimental impact of PPI use in high-risk
atients is related to CYP2C19 inhibition or another
echanism remains to be determined. Our study also
trongly suggests a need to further characterize particular
isk factors that may promote PPI interaction in these
igh-risk patients.
tudy limitations. First, the majority of studies were ob-
ervational, coming from prospective or retrospective regis-
ries. However, the Quality of Reporting of Meta-Analyses
tatement checklist was rigorously applied, allowing a care-
ul selection of studies with the systematic use of a quality
core, which are key factors to control for this limitation.
econd, our results are exposed to the usual limitations of
eta-analyses performed on global data. Thus, we per-
ormed sensitivity analyses for both CYP2C19*2 carriage
nd PPI use that led to similar conclusions irrespective of
he quality or the size of the studies. A fixed-effect model
as chosen because the selected studies had the same
opulation risk estimate, and the prevalence of stent throm-
osis and cardiovascular mortality are low, but the results
ere also confirmed when we used a random-effect model.
Because the data were not available, we were also unable to
valuate differences among various PPIs according to their
egrees of inhibition of the CYP2C19 isoenzyme or according
o CYP2C19 polymorphism status (19–21). Subsequently, a
gene-dose effect” of the CYP2C19*2 allele on the pharmaco-
inetics and pharmacodynamics of PPIs, which has been
reviously reported (46), could not be assessed in the present
eta-analysis. Finally, another bias of these selected datasets
as the inadequate or incomplete information on concurrent
spirin use and the bias represented by the fact that patients
reated with PPIs are likely to be at higher risk for both
leeding and ischemic events. It is thus unclear how much PPI
se is a marker of more severe morbid conditions and of higher
isk for adverse outcomes.
onclusions
ur meta-analysis suggests that CYP2C19*2 carriers and/or
PI users, who represent at least 50% of patients, are at
igher risk for severe cardiovascular events when they are
reated with clopidogrel. Whereas the impact of the
YP2C19*2 allele is observed in all patients, the impact of
PIs might only be significant in patients with high baseline
ardiovascular risk. Our findings support the recent update
n clopidogrel labeling, which now considers the impact of
YP2C19 alteration on the pharmacodynamic response to
lopidogrel with potential clinical consequences, especially
n patients who underwent recent stent implantation. Ge-
otype profile and PPI use deserve further attention and
tudies in patients exposed to clopidogrel before definitive
onclusions can be drawn (47).eprint requests and correspondence: Dr. Gilles Montalescot,
ureau 236, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, 47
oulevard de l’Hôpital, 75013 Paris, France. E-mail: gilles.
ontalescot@psl.aphp.fr.
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